300 ‘Junk Patents’ Targeted by FTC With Warning Letters, Including Ozempic

The Federal Trade Commission (FTC) continues slicing a machete through the patent thicket.

On Tuesday, the agency sent warning letters to 10 pharmaceutical companies threatening legal action for improperly listed patents, and notified the FDA that it disputes the accuracy or relevance of more than 300 Orange Book patent listings across 20 different brand name products.

This follows a similar move the FTC made in November involving 100 patents filed by pharma companies.

The latest spate of “junk patent” listings include medicines for diabetes, asthma, COPD, and weight loss, notably Novo Nordisk’s blockbuster injectable weight-loss drug, Ozempic.

To read the whole story, click here.

Related Topics